about
Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11λ-Dynamics free energy simulation methodsNovel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agentIn vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent anti-human immunodeficiency virus activityIn vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected catsImmunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.Ellagic acid & gallic acid from Lagerstroemia speciosa L. inhibit HIV-1 infection through inhibition of HIV-1 protease & reverse transcriptase activityEffects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.Efficiency of a programmed -1 ribosomal frameshift in the different subtypes of the human immunodeficiency virus type 1 group M.The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors.The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.
P2860
Q24534863-BF87F6CC-B0F9-4B28-996D-1BE4669D138EQ27489387-BCF8DF0B-93CB-43DB-8DDB-2F7442F66E48Q34113812-BA0E521D-32D5-4C37-A592-73BED992729AQ34141998-2734E8EB-0CED-4852-8100-667973E6BD26Q34734416-40B7BF27-0016-41AC-ABC1-FB187AD4BF4AQ34883567-6E49643F-0FE0-44C2-B246-FDD8FAAEC7C8Q35920633-FA75E93F-83E1-4AEB-B1E6-EF5CE8EC9260Q36994957-B7A3890E-84F8-4B32-BF74-E856F8595AA4Q40816072-81378B88-C4AE-449F-9891-BA52FCADC460Q41848089-E37E19BF-A514-469D-B6CF-FBB6E7612BF9Q43747959-0FAB412E-4098-4EB3-AD94-B2AE5FEE58BEQ44108845-B621F81C-671A-40F5-B3C7-3B6D8508A08DQ44467962-88D3B681-372F-4A43-B6A4-AAAF4BA81EFE
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Resistance against reverse transcriptase inhibitors.
@ast
Resistance against reverse transcriptase inhibitors.
@en
type
label
Resistance against reverse transcriptase inhibitors.
@ast
Resistance against reverse transcriptase inhibitors.
@en
prefLabel
Resistance against reverse transcriptase inhibitors.
@ast
Resistance against reverse transcriptase inhibitors.
@en
P356
P1476
Resistance against reverse transcriptase inhibitors.
@en
P2093
O'Brien WA
P304
P356
10.1086/313858
P407
P478
30 Suppl 2
P577
2000-06-01T00:00:00Z